Your browser is no longer supported. Please, upgrade your browser.
Cara Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.12 Insider Own2.30% Shs Outstand46.89M Perf Week6.09%
Market Cap928.01M Forward P/E- EPS next Y-1.76 Insider Trans-5.56% Shs Float41.81M Perf Month28.18%
Income-99.10M PEG- EPS next Q0.36 Inst Own68.80% Short Float9.18% Perf Quarter35.53%
Sales27.50M P/S33.75 EPS this Y-20.90% Inst Trans0.23% Short Ratio8.87 Perf Half Y8.62%
Book/sh2.73 P/B7.01 EPS next Y-44.30% ROA-53.20% Target Price- Perf Year17.20%
Cash/sh2.49 P/C7.68 EPS next 5Y- ROE-64.40% 52W Range8.88 - 21.64 Perf YTD26.57%
Dividend- P/FCF- EPS past 5Y-24.10% ROI-59.40% 52W High-11.51% Beta1.49
Dividend %- Quick Ratio8.00 Sales past 5Y44.30% Gross Margin- 52W Low115.65% ATR0.88
Employees76 Current Ratio8.00 Sales Q/Q60.30% Oper. Margin- RSI (14)69.74 Volatility7.00% 4.94%
OptionableYes Debt/Eq0.00 EPS Q/Q52.30% Profit Margin- Rel Volume1.10 Prev Close18.98
ShortableYes LT Debt/Eq0.00 EarningsNov 09 AMC Payout- Avg Volume432.71K Price19.15
Recom1.70 SMA2014.95% SMA5021.71% SMA20023.36% Volume477,141 Change0.90%
Apr-21-20Reiterated H.C. Wainwright Buy $30 → $33
Aug-12-19Reiterated H.C. Wainwright Buy $31 → $30
May-29-19Reiterated Laidlaw Buy $26 → $32
Feb-06-19Resumed Jefferies Buy $22
Jan-15-19Initiated BofA/Merrill Neutral $19
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-13-18Initiated Jefferies Buy $30
Aug-08-18Reiterated Stifel Buy $22 → $26
Jun-28-18Reiterated H.C. Wainwright Buy $24 → $26
Mar-12-18Resumed H.C. Wainwright Buy $22
Feb-12-18Upgrade Janney Neutral → Buy
Jan-19-18Initiated Seaport Global Securities Buy $27
Jun-30-17Reiterated Stifel Buy $24 → $20
Jun-30-17Reiterated Laidlaw Buy $35 → $30
Jun-30-17Downgrade Janney Buy → Neutral
Mar-28-17Reiterated Laidlaw Buy $20 → $35
Mar-28-17Reiterated H.C. Wainwright Buy $22 → $30
Mar-10-17Reiterated Laidlaw Buy $17 → $20
Oct-13-16Initiated H.C. Wainwright Buy $20
Aug-08-16Reiterated Needham Buy $27 → $23
Jan-11-21 07:00AM  
Jan-08-21 08:56AM  
Jan-06-21 07:00AM  
Dec-28-20 07:00AM  
Dec-24-20 07:30AM  
Dec-22-20 04:05PM  
Dec-18-20 12:19AM  
Dec-02-20 07:00AM  
Nov-17-20 01:16PM  
Nov-12-20 05:42AM  
Nov-11-20 07:00AM  
Nov-09-20 09:00PM  
Nov-02-20 04:01PM  
Oct-27-20 04:05PM  
Oct-22-20 12:00PM  
Oct-21-20 04:01PM  
Oct-20-20 03:30PM  
Oct-16-20 11:01AM  
Oct-14-20 12:57PM  
Oct-11-20 08:55AM  
Oct-01-20 07:00AM  
Aug-27-20 03:37PM  
Aug-11-20 05:30PM  
Aug-10-20 06:05PM  
Aug-06-20 04:01PM  
Aug-03-20 04:01PM  
Jul-29-20 12:33PM  
Jul-13-20 02:47PM  
Jul-08-20 01:34PM  
Jun-30-20 07:00AM  
Jun-25-20 06:04PM  
Jun-17-20 07:00AM  
May-27-20 04:01PM  
May-15-20 11:00AM  
May-12-20 06:00AM  
May-11-20 05:55PM  
May-07-20 07:00AM  
May-04-20 04:01PM  
Apr-29-20 07:14AM  
Apr-28-20 12:34PM  
Apr-21-20 08:07AM  
Apr-20-20 09:40AM  
Apr-08-20 07:00AM  
Mar-25-20 07:00AM  
Mar-23-20 06:49AM  
Mar-10-20 01:45PM  
Feb-29-20 08:05AM  
Feb-27-20 05:55PM  
Feb-20-20 04:01PM  
Feb-03-20 06:12AM  
Jan-15-20 05:26PM  
Jan-08-20 04:01PM  
Dec-19-19 09:32PM  
Dec-06-19 04:01PM  
Dec-04-19 10:02AM  
Dec-03-19 04:01PM  
Nov-13-19 09:12AM  
Nov-12-19 04:01PM  
Nov-11-19 07:00AM  
Nov-05-19 06:35PM  
Nov-01-19 07:00AM  
Oct-29-19 04:40PM  
Oct-20-19 08:45AM  
Oct-14-19 07:00AM  
Oct-01-19 02:23PM  
Sep-26-19 04:01PM  
Sep-19-19 10:11AM  
Aug-21-19 04:24PM  
Aug-19-19 12:34PM  
Aug-14-19 10:54AM  
Aug-05-19 10:21AM  
Jul-31-19 04:01PM  
Jul-29-19 04:01PM  
Jul-26-19 09:18PM  
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Terrillion ScottSec'y; Chief Compliance & G.C.Dec 30Sale15.301,94629,77442,436Dec 30 06:16 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DDec 30Sale15.302,81243,024109,680Dec 30 06:15 PM
Goncalves JoanaChief Medical OfficerDec 30Sale15.301,29819,85930,075Dec 30 06:14 PM
CHALMERS DEREK TPresident & CEODec 30Sale15.306,07892,993936,593Dec 30 06:12 PM
CHALMERS DEREK TPresident & CEODec 28Sale16.005,00080,000942,671Dec 29 06:41 PM
Goncalves JoanaChief Medical OfficerDec 21Sale15.002,00030,00027,373Dec 23 07:11 PM
CHALMERS DEREK TPresident & CEODec 16Sale14.955,00074,750928,921Dec 18 04:58 PM
CHALMERS DEREK TPresident & CEODec 10Sale15.297,500114,675933,921Dec 11 08:32 PM
Goncalves JoanaChief Medical OfficerNov 23Sale15.312,00030,62029,373Nov 25 04:48 PM
Posner ChristopherDirectorNov 19Sale15.822,00031,63811,200Nov 23 08:28 PM
CHALMERS DEREK TPresident & CEONov 17Sale16.0011,799188,784941,421Nov 19 05:29 PM
VOGELBAUM MARTINDirectorNov 17Sale16.096,00096,54014,400Nov 19 05:30 PM
Goncalves JoanaChief Medical OfficerNov 10Sale15.002,00030,00031,373Nov 13 05:39 PM
Goncalves JoanaChief Medical OfficerOct 20Sale15.002,00030,00033,373Oct 22 06:00 PM
CHALMERS DEREK TPresident & CEOSep 03Sale16.003,20151,216953,220Sep 08 05:22 PM
CHALMERS DEREK TPresident & CEOAug 03Sale16.425,00082,100956,421Aug 05 06:20 PM
CHALMERS DEREK TPresident & CEOJul 01Sale17.115,00085,550961,421Jul 02 04:40 PM
Goncalves JoanaChief Medical OfficerJun 12Sale15.2010,627161,53035,373Jun 12 06:00 PM
CHALMERS DEREK TPresident & CEOJun 03Sale16.014,30068,843966,421Jun 03 07:53 PM
Ives Jeffrey L.DirectorJun 01Option Exercise9.941,0009,9407,000Jun 03 07:51 PM
CHALMERS DEREK TPresident & CEOJun 01Sale16.0070011,200970,721Jun 03 07:53 PM
Ives Jeffrey L.DirectorJun 01Sale16.001,00016,0006,000Jun 03 07:51 PM
CHALMERS DEREK TPresident & CEOMay 22Sale16.003715,936971,421May 22 06:26 PM
CHALMERS DEREK TPresident & CEOMay 21Sale16.003,50056,000971,792May 22 06:26 PM
CHALMERS DEREK TPresident & CEOMay 20Sale16.001,20019,200975,292May 22 06:26 PM
Ives Jeffrey L.DirectorMay 12Option Exercise9.942,50024,8508,500May 14 08:02 PM
CHALMERS DEREK TPresident & CEOMay 12Sale16.004,92978,864976,492May 14 08:04 PM
Ives Jeffrey L.DirectorMay 12Sale16.002,50040,0006,000May 14 08:02 PM
Ives Jeffrey L.DirectorApr 21Option Exercise9.942,50024,8508,500Apr 21 07:09 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Apr 21Sale15.562,72142,33938,382Apr 21 06:50 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DApr 21Sale15.5812,894200,889104,492Apr 21 06:49 PM
CHALMERS DEREK TPresident & CEOApr 21Sale15.566,34898,775981,421Apr 21 06:47 PM
Ives Jeffrey L.DirectorApr 21Sale16.002,50040,0006,000Apr 21 07:09 PM
Ives Jeffrey L.DirectorMar 04Option Exercise9.942,50024,8508,500Mar 06 04:39 PM
Ives Jeffrey L.DirectorMar 04Sale16.002,50040,0006,000Mar 06 04:39 PM
Ives Jeffrey L.DirectorFeb 03Option Exercise9.942,50024,8508,500Feb 05 05:01 PM
Ives Jeffrey L.DirectorFeb 03Sale16.232,50040,5756,000Feb 05 05:01 PM